Abstract

RECENT ADVANCEMENTS AND FUTURE TREATMENTS FOR TRIPLE NEGATIVE BREAST CANCER

Sagar Ashok Vaidya* and H. J. Pagar

ABSTRACT

Triple-negative breast cancer (TNBC) is a subtype of breast cancer that lacks the expression of estrogen, progesterone, and HER2 receptors, and is associated with poor prognosis and high risk of metastasis. This paper reviews the current advances in the molecularly targeted therapies for TNBC, focusing on the role of the immune system and natural medications. It discusses the evidence for the efficacy of immune checkpoint inhibitors and poly (ADP-ribose) polymerase inhibitors, as well as the potential of natural drug extracts such as paclitaxel and curcumin. It also explores the challenges and opportunities for developing more effective and personalized treatments for TNBC patients.

Keywords: Triple-negative breast cancer (TNBC) is a subtype of breast cancer that lacks the expression of estrogen, progesterone, and HER2 receptors, and is associated with poor prognosis and high risk of metastasis. This paper reviews the current advances in the m